-
1
-
-
0036067568
-
Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization
-
Topol E.J., Lincoff A.M., Kereiakes D.J., et al. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am J Med 113 (2002) 1-6
-
(2002)
Am J Med
, vol.113
, pp. 1-6
-
-
Topol, E.J.1
Lincoff, A.M.2
Kereiakes, D.J.3
-
2
-
-
2242477091
-
Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation
-
Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 330 (1994) 956-961
-
(1994)
N Engl J Med
, vol.330
, pp. 956-961
-
-
-
3
-
-
33845709129
-
A randomized study comparing same-day home discharge and abciximab bolus only to overnight hospitalization and abciximab bolus and infusion after transradial coronary stent implantation
-
Bertrand O.F., De Larochelliere R., Rodes-Cabau J., et al. A randomized study comparing same-day home discharge and abciximab bolus only to overnight hospitalization and abciximab bolus and infusion after transradial coronary stent implantation. Circulation 114 (2006) 2636-2643
-
(2006)
Circulation
, vol.114
, pp. 2636-2643
-
-
Bertrand, O.F.1
De Larochelliere, R.2
Rodes-Cabau, J.3
-
4
-
-
0035195534
-
American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee)
-
Cannon C.P., Battler A., Brindis R.G., et al. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). J Am Coll Cardiol 38 (2001) 2114-2130
-
(2001)
J Am Coll Cardiol
, vol.38
, pp. 2114-2130
-
-
Cannon, C.P.1
Battler, A.2
Brindis, R.G.3
-
5
-
-
33645507439
-
Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial
-
Kastrati A., Mehilli J., Neumann F.J., et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. Jama 295 (2006) 1531-1538
-
(2006)
Jama
, vol.295
, pp. 1531-1538
-
-
Kastrati, A.1
Mehilli, J.2
Neumann, F.J.3
-
6
-
-
9144228045
-
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel
-
Kastrati A., Mehilli J., Schuhlen H., et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 350 (2004) 232-238
-
(2004)
N Engl J Med
, vol.350
, pp. 232-238
-
-
Kastrati, A.1
Mehilli, J.2
Schuhlen, H.3
-
7
-
-
0028117857
-
Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty
-
Tcheng J.E., Ellis S.G., George B.S., et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 90 (1994) 1757-1764
-
(1994)
Circulation
, vol.90
, pp. 1757-1764
-
-
Tcheng, J.E.1
Ellis, S.G.2
George, B.S.3
-
8
-
-
33749331837
-
High-dose, single-bolus eptifibatide: a safe and cost-effective alternative to conventional glycoprotein IIb/IIIa inhibitor use for elective coronary interventions
-
Fischell T.A., Attia T., Rane S., et al. High-dose, single-bolus eptifibatide: a safe and cost-effective alternative to conventional glycoprotein IIb/IIIa inhibitor use for elective coronary interventions. J Invasive Cardiol 18 (2006) 487-491
-
(2006)
J Invasive Cardiol
, vol.18
, pp. 487-491
-
-
Fischell, T.A.1
Attia, T.2
Rane, S.3
-
9
-
-
33750700519
-
Bolus-only platelet glycoprotein IIb-IIIa inhibition during percutaneous coronary intervention
-
Marmur J.D., Poludasu S., Agarwal A., et al. Bolus-only platelet glycoprotein IIb-IIIa inhibition during percutaneous coronary intervention. J Invasive Cardiol 18 (2006) 521-526
-
(2006)
J Invasive Cardiol
, vol.18
, pp. 521-526
-
-
Marmur, J.D.1
Poludasu, S.2
Agarwal, A.3
-
10
-
-
33750300540
-
Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial
-
Marmur J.D., Mitre C.A., Barnathan E., et al. Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial. Am Heart J 152 (2006) 876-881
-
(2006)
Am Heart J
, vol.152
, pp. 876-881
-
-
Marmur, J.D.1
Mitre, C.A.2
Barnathan, E.3
-
11
-
-
0037145863
-
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial
-
Steinhubl S.R., Berger P.B., Mann III J.T., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002) 2411-2420
-
(2002)
JAMA
, vol.288
, pp. 2411-2420
-
-
Steinhubl, S.R.1
Berger, P.B.2
Mann III, J.T.3
-
12
-
-
9644291514
-
Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization
-
Kandzari D.E., Berger P.B., Kastrati A., et al. Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. J Am Coll Cardiol 44 (2004) 2133-2136
-
(2004)
J Am Coll Cardiol
, vol.44
, pp. 2133-2136
-
-
Kandzari, D.E.1
Berger, P.B.2
Kastrati, A.3
-
13
-
-
4944261759
-
Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy
-
Kastrati A., von Beckerath N., Joost A., et al. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation 110 (2004) 1916-1919
-
(2004)
Circulation
, vol.110
, pp. 1916-1919
-
-
Kastrati, A.1
von Beckerath, N.2
Joost, A.3
-
14
-
-
33644587565
-
Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention
-
Steinhubl S.R., Berger P.B., Brennan D.M., et al. Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. J Am Coll Cardiol 47 (2006) 939-943
-
(2006)
J Am Coll Cardiol
, vol.47
, pp. 939-943
-
-
Steinhubl, S.R.1
Berger, P.B.2
Brennan, D.M.3
-
15
-
-
0035887138
-
-
Assali AR, Salloum J, Sdringola S, et al. Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban). Am J Cardiol 2001;88:884-6, A6.
-
Assali AR, Salloum J, Sdringola S, et al. Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban). Am J Cardiol 2001;88:884-6, A6.
-
-
-
-
16
-
-
0037151685
-
Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial)
-
Bonz A.W., Lengenfelder B., Strotmann J., et al. Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial). J Am Coll Cardiol 40 (2002) 662-668
-
(2002)
J Am Coll Cardiol
, vol.40
, pp. 662-668
-
-
Bonz, A.W.1
Lengenfelder, B.2
Strotmann, J.3
-
17
-
-
3242785367
-
Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoPro Give Similar Efficacy Outcome Trial (TARGET)
-
Chan A.W., Moliterno D.J., Berger P.B., et al. Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoPro Give Similar Efficacy Outcome Trial (TARGET). J Am Coll Cardiol 42 (2003) 1188-1195
-
(2003)
J Am Coll Cardiol
, vol.42
, pp. 1188-1195
-
-
Chan, A.W.1
Moliterno, D.J.2
Berger, P.B.3
-
18
-
-
14944378655
-
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading with Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study
-
Gurbel P.A., Bliden K.P., Zaman K.A., et al. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading with Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation 111 (2005) 1153-1159
-
(2005)
Circulation
, vol.111
, pp. 1153-1159
-
-
Gurbel, P.A.1
Bliden, K.P.2
Zaman, K.A.3
-
19
-
-
33645052218
-
ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention)
-
Smith Jr. S.C., Feldman T.E., Hirshfeld Jr. J.W., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 113 (2006) e166-e286
-
(2006)
Circulation
, vol.113
-
-
Smith Jr., S.C.1
Feldman, T.E.2
Hirshfeld Jr., J.W.3
-
20
-
-
19244387281
-
Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction
-
Neumann F.J., Kastrati A., Schmitt C., et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol 35 (2000) 915-921
-
(2000)
J Am Coll Cardiol
, vol.35
, pp. 915-921
-
-
Neumann, F.J.1
Kastrati, A.2
Schmitt, C.3
-
21
-
-
0028345255
-
Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators
-
Topol E.J., Califf R.M., Weisman H.F., et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet 343 (1994) 881-886
-
(1994)
Lancet
, vol.343
, pp. 881-886
-
-
Topol, E.J.1
Califf, R.M.2
Weisman, H.F.3
-
22
-
-
20244385431
-
Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention
-
Anderson K.M., Califf R.M., Stone G.W., et al. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 37 (2001) 2059-2065
-
(2001)
J Am Coll Cardiol
, vol.37
, pp. 2059-2065
-
-
Anderson, K.M.1
Califf, R.M.2
Stone, G.W.3
-
23
-
-
3843060250
-
Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial
-
Lincoff A.M., Kleiman N.S., Kereiakes D.J., et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. Jama 292 (2004) 696-703
-
(2004)
Jama
, vol.292
, pp. 696-703
-
-
Lincoff, A.M.1
Kleiman, N.S.2
Kereiakes, D.J.3
-
24
-
-
27944459673
-
Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up
-
Mukherjee D., Topol E.J., Bertrand M.E., et al. Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up. Eur Heart J 26 (2005) 2524-2528
-
(2005)
Eur Heart J
, vol.26
, pp. 2524-2528
-
-
Mukherjee, D.1
Topol, E.J.2
Bertrand, M.E.3
-
25
-
-
33947575142
-
Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial
-
Manoukian S.V., Feit F., Mehran R., et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol 49 (2007) 1362-1368
-
(2007)
J Am Coll Cardiol
, vol.49
, pp. 1362-1368
-
-
Manoukian, S.V.1
Feit, F.2
Mehran, R.3
-
26
-
-
33947187284
-
Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial
-
Stone G.W., White H.D., Ohman E.M., et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 369 (2007) 907-919
-
(2007)
Lancet
, vol.369
, pp. 907-919
-
-
Stone, G.W.1
White, H.D.2
Ohman, E.M.3
|